{"id":"W3191692701","doi":"10.1038/s41591-021-01455-x","title":"Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial","year":2021,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Agence Nationale de la Recherche","keywords":"Progressive supranuclear palsy; Placebo; Discontinuation; Clinical endpoint; Medicine; Internal medicine; Surrogate endpoint; Randomized controlled trial; Adverse effect; Clinical trial; Gastroenterology; Pathology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001138548,0.0003814216,0.002902257,0.0002882248,0.00006767629,0.00001031728,0.00008804135,0.000395554,0.0004509754],"category_scores_gemma":[0.002854173,0.0002446592,0.0003212469,0.0004448784,0.0003131087,0.00006464194,0.00004805906,0.000684552,0.000004599578],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005819269,"about_ca_system_score_gemma":0.000278214,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002394364,"about_ca_topic_score_gemma":0.000005354944,"domain_scores_codex":[0.9969193,0.000469345,0.0009404321,0.0005866523,0.000713823,0.0003704748],"domain_scores_gemma":[0.9977018,0.0009851467,0.000364388,0.0003754325,0.0002542223,0.0003190104],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9808215,0.002843256,0.0003555798,0.0001741986,0.0009766477,0.003071024,0.0003676707,0.000001643503,0.006558932,0.0004061949,0.0001055292,0.004317745],"study_design_scores_gemma":[0.9883974,0.001444313,0.002815497,0.0009600809,0.001747931,0.0002368684,0.0001384375,0.0004923326,0.002174276,0.0001173434,0.001296401,0.0001790955],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9648302,0.02620432,0.00005152442,0.002554715,0.0004991233,0.004811394,0.00004904146,0.00004077272,0.000958896],"genre_scores_gemma":[0.9964488,0.001587606,0.0003966849,0.0004210006,0.0004242903,0.0001087125,0.0003865878,0.00003812189,0.0001882619],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03161852,"threshold_uncertainty_score":0.9976914,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008747660753057256,"score_gpt":0.3242055735514162,"score_spread":0.3154579127983589,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}